Infinitus named one of top 500 manufacturing enterprises in Guangdong for 2021
GUANGZHOU, China, Jan. 18, 2022 /PRNewswire/-- Infinitus, a leading provider of high-quality Chinese herbal health products and services, has been shortlisted as one of "2021 Top 500 Manufacturing Enterprises in Guangdong Province", joined by Huawei and Gree, among other Chinese name brands on the list. In 2021, manufacturing worldwide experienced a slow-down in its recovery while facing increasing...
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment
Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) A significant milestone in our pipeline development just after sugemalimab was approved for first-line treatment of stage IV non-small cell lung cancer (NSCLC) in China, we submitted an NDA to...
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase 2b clinical trial of XW003 in patients with obesity. XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at...
CYMBIOTIKA EXPANDS INTO AUSTRALIAN MARKET WITH LAUNCH OF NEW WEBSITE
Leading nutritional supplement brand reaffirms long-term growth in 2022 with international e-commerce platform launch SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cymbiotika, a leading nutritional supplement brand known for creating pure, clinically-backed supplements, today announced the launch of its new Australian website along with a fulfillment center in Victoria. The website will...
Menarini Diagnostics CoronaMeltVAR Real-Time PCR kit simultaneously detects SARS CoV-2 and identifies the Omicron Variant
FLORENCE, Italy, Jan. 17, 2022 /PRNewswire/ -- The new Omicron variant is spreading rapidly causing an increase in infections at unprecedented speed. On November 28th, WHO officially recommended laboratories to use Real Time PCR detection kits capable of identifying putative Omicron variant infections, directly at the moment of the positivity test. ...
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a...
Seegene’s Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada’s Interim Order
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order on January 11. Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay is a multiplex real-time PCR assay that...
Seegene Continues to Support Israel’s Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests to Israel to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 million diagnostic tests and associated consumables in...
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatment group obtained HBsAg loss versus no subject achieved...
HTPE Leads JYSSBIO to Close Series B+ Funding
HANGZHOU, China, Jan. 17, 2022 /PRNewswire/ -- Huatai International Private Equity Fund ("HTPE"), the Greater China focused private equity investment platform under Huatai Securities, is pleased to announce that it led the Series B+ financing of Zhejiang JYSS Bio-Engineering Co., Ltd. ("JYSSBIO" or the "Company"), a leading biotech manufacturing equipment and solutions company in China, to power its growth plan for...
